---
figid: PMC6281417__oncotarget-09-36151-g007
figtitle: Human liver stem cell-derived extracellular vesicles enhance cancer stem
  cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined modulation
organisms:
- Bos taurus
- Oryctolagus cuniculus
- Capra hircus
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Bos taurus
- Oryctolagus cuniculus
- Capra hircus
- Drosophila melanogaster
pmcid: PMC6281417
filename: oncotarget-09-36151-g007.jpg
figlink: /pmc/articles/PMC6281417/figure/F7/
number: F7
caption: Schematic representation of the inhibitory effect of HLSC-EVs and of TKIs
  alone or in combination on PI3K pathway and Erk. In particular, the co-administration
  of HLSC-EVs/TKIs exerted a synergistic effect (orange bars) on the inhibition of
  Akt and mTOR pathways and on pPTEN. HLSC-EVs alone (red bars) showed an inhibitory
  effect on Akt, mTOR pathways and on transcription factor Creb. Sunitinib or Sorafenib
  alone (yellow bars) inhibit RAS and mTOR pathways.
papertitle: Human liver stem cell-derived extracellular vesicles enhance cancer stem
  cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined modulation.
reftext: Valentina Fonsato, et al. Oncotarget. 2018 Nov 16;9(90):36151-36165.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9639532
figid_alias: PMC6281417__F7
figtype: Figure
redirect_from: /figures/PMC6281417__F7
ndex: 36e709ea-ded6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6281417__oncotarget-09-36151-g007.html
  '@type': Dataset
  description: Schematic representation of the inhibitory effect of HLSC-EVs and of
    TKIs alone or in combination on PI3K pathway and Erk. In particular, the co-administration
    of HLSC-EVs/TKIs exerted a synergistic effect (orange bars) on the inhibition
    of Akt and mTOR pathways and on pPTEN. HLSC-EVs alone (red bars) showed an inhibitory
    effect on Akt, mTOR pathways and on transcription factor Creb. Sunitinib or Sorafenib
    alone (yellow bars) inhibit RAS and mTOR pathways.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Pten
  - Akt1
  - Zhx2
  - Mtor
  - Ephb2
  - Mapk1
  - Creb1
  - Mdk
  - Tk2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - TK2
  - TK1
  - Tie
  - Ras85D
  - InR
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Ras64B
  - Akt
  - Raf
  - Tor
  - Erk7
  - rl
  - CrebB
  - CrebA
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Dsor1
  - Mtk
  - btl
  - Sunitinib
  - Sorafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
